Close Menu

NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 6 percent year over year, driven in part by growth in its sample-to-answer molecular product sales.

For the three months ended March 31, the firm reported revenues of $82.7 million, up from $77.8 million a year ago, and beating the consensus Wall Street estimate of $80.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.